Excerpt
SUMMARY: Each year, superbugs -- viral bacterial infections resistant to common antibiotics -- infect more than two million Americans, killing at least 38,000. As the list of antibiotic-resistant bacteria grows, so have the extraordinary efforts to prevent the spread of infection from patient to patient. Science correspondent Miles O'Brien and economics correspondent Paul Solman team up for a report.
"The financial barrier to developing antibiotics? No big payday for drug companies" PBS NewsHour 8/3/2017
Excerpt
SUMMARY: As current antibiotics begin to lose their punch, there's an economic reality putting a damper on development. Since every use of an antibiotic drives resistance, and doctors are reluctant to use a drug until there's no alternative, why would a drug company spend a fortune? Economics correspondent Paul Solman and science correspondent Miles O'Brien continue their look at the hunt for new drugs.
"Drug companies aren't making new antibiotics. Is there an economic cure?" PBS NewsHour 8/4/2017
Excerpt
SUMMARY: As drug-resistant infections proliferate, financial barriers are preventing the pharmaceutical industry from investing in new drugs to fight off superbugs. Economics correspondent Paul Solman, in a series of reports with science correspondent Miles O'Brien, explores how researchers could be incentivized to develop new antibiotics.
No comments:
Post a Comment